News & Events about Exelixis Inc.
Exelixis (NASDAQ:EXEL Get Rating) had its target price cut by JMP Securities from $25.00 to $24.00 in a research note published on Thursday, Benzinga reports. They currently have a market outperform rating on the biotechnology companys stock. A number of other brokerages have also recently weighed ...
Latest Ratings for EXEL
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for EXEL
View the Latest Analyst Ratings
read more...
Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC). Zanzalintinib, which was adopted as the generic name...
Business Wire
3 months ago
Exelixis, Inc. (Nasdaq: EXEL) today announced promising initial results from the ongoing dose-escalation stage of JEWEL-101, a phase 1 study evaluating XB002, Exelixis next-generation tissue factor-targeting antibody-drug conjugate. The data are being presented on Friday, October 28 during the...